(HLN) Haleon - Ratings and Ratios
Toothpaste, Vitamins, Pain-Relief, Antacids, Cold-Remedies
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 20.3% |
| Value at Risk 5%th | 33.9% |
| Relative Tail Risk | 1.45% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.19 |
| Alpha | -0.24 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.509 |
| Beta | 0.235 |
| Beta Downside | 0.058 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.11% |
| Mean DD | 6.90% |
| Median DD | 6.51% |
Description: HLN Haleon September 29, 2025
Haleon plc (NYSE:HLN) is a global consumer-health company that designs, manufactures, and markets a portfolio of over-the-counter (OTC) products across North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. Its core categories include oral-care (Sensodyne, Polident, Parodontax, Aquafresh, Biotene), vitamins and supplements (Centrum, Emergen-C, Caltrate), respiratory relief (Otrivine, Theraflu, Flonase), pain and anti-inflammatory agents (Voltaren, Panadol, Advil), and digestive health (TUMS, ENO, Fenistil).
Formed from the spin-off of GSK’s consumer-health business in 2022, Haleon inherited legacy brands and a historic lineage dating back to 1715, with its headquarters in Weybridge, United Kingdom. The company trades as a common stock under the ticker HLN and is classified in the GICS sub-industry “Biotechnology,” reflecting its focus on health-related consumer products rather than prescription drugs.
According to the most recent FY 2023 filing, Haleon reported net sales of approximately $5.7 billion, a 3.2 % year-over-year increase driven largely by strong demand for its oral-care and vitamin lines in the United States and Europe. Adjusted earnings per share rose to $2.10, and the firm maintained a dividend yield near 2.5 %, underscoring its commitment to returning cash to shareholders while funding incremental R&D and marketing spend.
Key macro drivers for Haleon include the aging global population, which expands the market for vitamins, joint-pain relief, and digestive health products, and a post-pandemic shift toward self-managed health care that is boosting OTC sales at a compound annual growth rate of roughly 4 % worldwide. Additionally, inflationary pressure on consumer discretionary spending creates pricing discipline, but Haleon’s premium-brand positioning and cost-efficiency initiatives have helped preserve operating margins above the sector average.
For a deeper, data-rich assessment of Haleon’s valuation metrics and competitive positioning, you may find it worthwhile to explore the analyst tools available on ValueRay.
HLN Stock Overview
| Market Cap in USD | 44,016m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2022-07-22 |
| Return 12m vs S&P 500 | -6.33% |
| Analyst Rating | 4.0 of 5 |
HLN Dividends
| Metric | Value |
|---|---|
| Dividend Yield | 1.78% |
| Yield on Cost 5y | 2.46% |
| Yield CAGR 5y | 50.96% |
| Payout Consistency | 100.0% |
| Payout Ratio | 48.2% |
HLN Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | 14.61% |
| CAGR/Max DD Calmar Ratio | 0.63 |
| CAGR/Mean DD Pain Ratio | 2.12 |
| Current Volume | 9937.3k |
| Average Volume | 9624.5k |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (1.52b TTM) > 0 and > 6% of Revenue (6% = 661.1m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -2.36pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -5.63% (prev -8.12%; Δ 2.49pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 3.33b > Net Income 1.52b (YES >=105%, WARN >=100%) |
| Net Debt (7.78b) to EBITDA (2.66b) ratio: 2.93 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (4.53b) change vs 12m ago -1.61% (target <= -2.0% for YES) |
| Gross Margin 62.94% (prev 60.68%; Δ 2.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 33.79% (prev 33.71%; Δ 0.08pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.22 (EBITDA TTM 2.66b / Interest Expense TTM 330.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.21
| (A) -0.02 = (Total Current Assets 4.14b - Total Current Liabilities 4.76b) / Total Assets 31.83b |
| (B) 0.86 = Retained Earnings (Balance) 27.27b / Total Assets 31.83b |
| warn (B) unusual magnitude: 0.86 — check mapping/units |
| (C) 0.07 = EBIT TTM 2.38b / Avg Total Assets 32.61b |
| (D) 1.01 = Book Value of Equity 15.94b / Total Liabilities 15.83b |
| Total Rating: 4.21 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 52.50
| 1. Piotroski 5.50pt |
| 2. FCF Yield 2.25% |
| 3. FCF Margin 8.45% |
| 4. Debt/Equity 0.53 |
| 5. Debt/Ebitda 2.93 |
| 6. ROIC - WACC (= 1.54)% |
| 7. RoE 9.40% |
| 8. Rev. Trend -55.27% |
| 9. EPS Trend -9.98% |
What is the price of HLN shares?
Over the past week, the price has changed by +2.92%, over one month by +5.79%, over three months by +0.61% and over the past year by +5.25%.
Is HLN a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the HLN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.5 | 16.8% |
| Analysts Target Price | 11.5 | 16.8% |
| ValueRay Target Price | 10.8 | 9.5% |
HLN Fundamental Data Overview November 17, 2025
P/E Trailing = 21.7955
P/E Forward = 18.2149
P/S = 3.9945
P/B = 2.0407
P/EG = 2.8486
Beta = 0.23
Revenue TTM = 11.02b GBP
EBIT TTM = 2.38b GBP
EBITDA TTM = 2.66b GBP
Long Term Debt = 7.58b GBP (from longTermDebt, last quarter)
Short Term Debt = 813.0m GBP (from shortTermDebt, last quarter)
Debt = 8.45b GBP (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.78b GBP (from netDebt column, last quarter)
Enterprise Value = 41.39b GBP (33.61b + Debt 8.45b - CCE 676.0m)
Interest Coverage Ratio = 7.22 (Ebit TTM 2.38b / Interest Expense TTM 330.0m)
FCF Yield = 2.25% (FCF TTM 931.0m / Enterprise Value 41.39b)
FCF Margin = 8.45% (FCF TTM 931.0m / Revenue TTM 11.02b)
Net Margin = 13.81% (Net Income TTM 1.52b / Revenue TTM 11.02b)
Gross Margin = 62.94% ((Revenue TTM 11.02b - Cost of Revenue TTM 4.08b) / Revenue TTM)
Gross Margin QoQ = 64.51% (prev 64.51%)
Tobins Q-Ratio = 1.30 (Enterprise Value 41.39b / Total Assets 31.83b)
Interest Expense / Debt = 0.76% (Interest Expense 64.5m / Debt 8.45b)
Taxrate = 24.37% (131.0m / 537.5m)
NOPAT = 1.80b (EBIT 2.38b * (1 - 24.37%))
Current Ratio = 0.87 (Total Current Assets 4.14b / Total Current Liabilities 4.76b)
Debt / Equity = 0.53 (Debt 8.45b / totalStockholderEquity, last quarter 15.94b)
Debt / EBITDA = 2.93 (Net Debt 7.78b / EBITDA 2.66b)
Debt / FCF = 8.35 (Net Debt 7.78b / FCF TTM 931.0m)
Total Stockholder Equity = 16.19b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.78% (Net Income 1.52b / Total Assets 31.83b)
RoE = 9.40% (Net Income TTM 1.52b / Total Stockholder Equity 16.19b)
RoCE = 10.03% (EBIT 2.38b / Capital Employed (Equity 16.19b + L.T.Debt 7.58b))
RoIC = 7.15% (NOPAT 1.80b / Invested Capital 25.20b)
WACC = 5.61% (E(33.61b)/V(42.07b) * Re(6.88%) + D(8.45b)/V(42.07b) * Rd(0.76%) * (1-Tc(0.24)))
Discount Rate = 6.88% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -1.00%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈1.26b ; Y1≈830.0m ; Y5≈379.6m
Fair Price DCF = 1.68 (DCF Value 7.46b / Shares Outstanding 4.45b; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -9.98 | EPS CAGR: 0.57% | SUE: -0.02 | # QB: 0
Revenue Correlation: -55.27 | Revenue CAGR: -1.94% | SUE: 0.10 | # QB: 0
Additional Sources for HLN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle